After reports of blood clot formations in vaccinated individuals, health authorities in Denmark, Norway, and Iceland have halted the use of Oxford-AstraZeneca’s experimental COVID-19 vaccine on March 11. The European Medicines Agency (EMA), however, said that there was no indication that the “vaccine” was linked to the risk of blood clots, maintaining that its benefits outweigh its drawbacks. The EMA said the “vaccine” can continue to be administered during the investigation.
This incident follows the death of a 49-year-old Austrian woman who developed severe coagulation after receiving an AstraZeneca shot. Austrian health authorities suspended the use of the vaccine on March 7 and are investigating the death. We’d like to remind readers that most COVID-19 vaccines across the globe are authorized for emergency use only and have not completed their clinical trials.
On March 1, scientists and doctors issued an open letter to the EMA, urging it to withdraw the authorization of COVID vaccines or answer urgent safety questions about them. The group has called the EMA’s approval of vaccines “premature and reckless,” citing a violation of the Nuremberg ethics code against human experimentation.